JP2010521516A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521516A5 JP2010521516A5 JP2009554019A JP2009554019A JP2010521516A5 JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5 JP 2009554019 A JP2009554019 A JP 2009554019A JP 2009554019 A JP2009554019 A JP 2009554019A JP 2010521516 A5 JP2010521516 A5 JP 2010521516A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- compound
- treatment
- formula
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000002193 Pain Diseases 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010065390 Inflammatory pain Diseases 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 208000009935 visceral pain Diseases 0.000 claims 3
- RLSVXSYZCDEJGN-UHFFFAOYSA-N 3-(3-fluorophenyl)sulfonyl-8-piperazin-1-ylquinoline Chemical compound FC1=CC=CC(S(=O)(=O)C=2C=C3C=CC=C(C3=NC=2)N2CCNCC2)=C1 RLSVXSYZCDEJGN-UHFFFAOYSA-N 0.000 claims 1
- JJZFWROHYSMCMU-UHFFFAOYSA-N 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline Chemical compound C=1N=C2C(N3CCNCC3)=CC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 JJZFWROHYSMCMU-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0705424A GB0705424D0 (en) | 2007-03-21 | 2007-03-21 | Use of compounds in the treatment of pain and irritable bowel syndrome |
| GB0712390A GB0712390D0 (en) | 2007-06-26 | 2007-06-26 | Use of compounds in the treatment of pain and irritable bowel syndrome |
| PCT/EP2008/053285 WO2008113818A1 (en) | 2007-03-21 | 2008-03-19 | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010521516A JP2010521516A (ja) | 2010-06-24 |
| JP2010521516A5 true JP2010521516A5 (OSRAM) | 2011-04-28 |
Family
ID=39564633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554019A Ceased JP2010521516A (ja) | 2007-03-21 | 2008-03-19 | 疼痛および過敏性腸症候群の治療におけるキノリン誘導体の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100041672A1 (OSRAM) |
| EP (1) | EP2120950B1 (OSRAM) |
| JP (1) | JP2010521516A (OSRAM) |
| ES (1) | ES2389958T3 (OSRAM) |
| WO (1) | WO2008113818A1 (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20060100T3 (en) | 2003-07-22 | 2007-03-31 | Arena Pharmaceuticals Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| NZ579735A (en) | 2007-03-23 | 2012-02-24 | Abbott Gmbh & Co Kg | Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| EP2763676B1 (en) | 2011-10-03 | 2019-12-25 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| EP2822641B1 (en) * | 2012-03-08 | 2019-06-19 | SPR Therapeutics, Inc. | System for treatment of pain related to limb joint replacement surgery |
| US20160038484A1 (en) * | 2013-04-03 | 2016-02-11 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CA3012900A1 (en) * | 2016-02-05 | 2017-08-10 | Pharnext | Novel combinatorial therapies of neurological disorders |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
| US5576338A (en) * | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| US20010051719A1 (en) * | 1996-12-19 | 2001-12-13 | Smithkline Beecham P.L.C. | Novel compounds |
| US6207679B1 (en) * | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
| US6376670B1 (en) * | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| US6172084B1 (en) * | 1997-06-19 | 2001-01-09 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| TR200000073T2 (tr) * | 1997-07-11 | 2000-06-21 | Smithkline Beecham P.L.C. | 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi |
| GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| US6403808B1 (en) * | 1999-12-10 | 2002-06-11 | Virginia Commonwealth University | Selective 5-HT6 receptor ligands |
| US6310212B1 (en) * | 2000-03-28 | 2001-10-30 | Neurogen Corporation | 4-substituted quinoline derivatives |
| GB0021450D0 (en) * | 2000-08-31 | 2000-10-18 | Smithkline Beecham Plc | Novel compounds |
| WO2002032863A1 (en) * | 2000-10-20 | 2002-04-25 | Biovitrum Ab | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| DE10053813A1 (de) * | 2000-10-30 | 2002-05-08 | Bayer Ag | Neue Verwendung von Sulfonamiden |
| JP2004517826A (ja) * | 2000-11-21 | 2004-06-17 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Ｃｎｓ障害の治療において有用なイソキノリン誘導体 |
| EP1335722B1 (en) * | 2000-11-24 | 2006-08-30 | Smithkline Beecham Plc | Indolyl-sulfonyl- compounds useful in the treatment of cns disorders |
| SK16052003A3 (en) * | 2001-06-07 | 2004-10-05 | Hoffmann La Roche | New indole derivatives with 5-HT6 receptor affinity |
| ITRM20010356A1 (it) * | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| EP1456178A1 (en) * | 2001-12-21 | 2004-09-15 | Smithkline Beecham Plc | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| WO2003065046A2 (en) * | 2002-02-01 | 2003-08-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| DE60304695T2 (de) * | 2002-02-13 | 2006-09-21 | Glaxo Group Ltd., Greenford | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems |
| ATE398108T1 (de) * | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| US7943639B2 (en) * | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
| DE60316180T2 (de) * | 2002-12-03 | 2008-05-29 | F. Hoffmann-La Roche Ag | Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten |
| MXPA05008441A (es) * | 2003-02-14 | 2005-10-19 | Wyeth Corp | Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6. |
| GB0305575D0 (en) * | 2003-03-11 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| GB0322510D0 (en) * | 2003-09-25 | 2003-10-29 | Glaxo Group Ltd | Novel compounds |
| PT1667975E (pt) * | 2003-09-26 | 2008-02-29 | Glaxo Group Ltd | Forma polimórfica de 3-fenilsulfonil-8-piperazin-1-il-quinolina |
| SE0302760D0 (sv) * | 2003-10-20 | 2003-10-20 | Biovitrum Ab | New compounds |
| WO2005066157A1 (en) * | 2004-01-02 | 2005-07-21 | Suven Life Sciences | 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators |
| GB0407025D0 (en) * | 2004-03-29 | 2004-04-28 | Glaxo Group Ltd | Novel compounds |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| WO2005121140A1 (en) * | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
| GB0425548D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Radiolabelled ligands |
-
2008
- 2008-03-19 ES ES08718011T patent/ES2389958T3/es active Active
- 2008-03-19 WO PCT/EP2008/053285 patent/WO2008113818A1/en not_active Ceased
- 2008-03-19 EP EP08718011A patent/EP2120950B1/en not_active Not-in-force
- 2008-03-19 US US12/531,896 patent/US20100041672A1/en not_active Abandoned
- 2008-03-19 JP JP2009554019A patent/JP2010521516A/ja not_active Ceased